Clinical Associations

B-Cell Chronic Lymphocytic Leukemia–Associated Pure Red Cell Aplasia

In B-cell chronic lymphocytic leukemia (CLL), PRCA can be observed in up to 6% of cases. A recent study found 0.5% of their 1750 CLL patients has PRCA. This diagnosis should be considered in CLL patients who demonstrate anemia and reticulocytopenia. Definite diagnosis requires bone marrow biopsy which will show absence of erythroid precursors and red cell aplasia. The underlying pathogenetic mechanisms are not clear, and the inhibition of the erythroid series does not appear to be mediated by a soluble factor. The distinction between whether the PRCA is a result of the primary B-cell CLL disease or its therapy becomes difficult in circumstances when PRCA presents as a late event. In most cases, PRCA cannot be attributed simply to infiltration of the marrow by lymphoma cells.

T-Cell Large Granular Lymphocyte–Associated Pure Red Cell Aplasia

Although neutropenia is a typical finding in T-LGL leukemia, PRCA with varying degrees of erythroblastopenia can also be observed in 10% to 68% of patients with T-LGL leukemia, with much higher rates in Asian populations. It is found to be commonly associated with signal transducer and activator of transcription (STAT)3 mutant T-LGL leukemia. In such a setting, PRCA is often accompanied by red cells with an increased mean corpuscular volume. It is possible that PRCA associated with T-LGL leukemia represents an extreme form of the T-cell–mediated disease that, if polyclonal, might be classified as idiopathic PRCA.

Thymoma-Associated Pure Red Cell Aplasia

Thymoma is associated with PRCA; thus a chest X-ray examination or computed tomographic (CT) scan should be included in the workup for PRCA. Antibodies with direct inhibitory effects against erythroid precursors may be present. T-cell–mediated inhibition of erythropoiesis has also been implicated in the pathogenesis of PRCA associated with either benign or malignant thymomas. A late onset immunodeficiency condition, Good syndrome, which is characterized by hypogammaglobulinemia and thymoma is associated with PRCA in 33% of the patients. Thymectomy is the usual initial treatment approach; however, incomplete responders, nonresponders, and patients who relapse are common, necessitating additional therapies in the form of azathioprine, intravenous immunoglobulins (IVIg), and cyclosporine A (CsA).

Pregnancy-Associated Pure Red Cell Aplasia

Pregnancy-associated PRCA is a self-limited syndrome that may occur at any age of gestation. It has a high risk for relapse during subsequent pregnancies and can be safely managed with either blood transfusions or corticosteroids. Patients with other forms of PRCA may also be more prone to relapse during pregnancy.

Parvovirus B19 and Other Viral-Induced Pure Red Cell Aplasias

Parvovirus B19 is a single-stranded deoxyribonucleic acid (DNA) virus, which in normal individuals causes fifth disease (erythema infectiosum) in children and arthropathy in adults. It is of particular concern in patients with sickle cell disease. The cellular receptor for the virus is the P antigen, a blood group antigen also responsible for the agglutination reaction that occurs in the presence of the virus. Detection of parvovirus B19–specific IgM without antiparvovirus B19 IgG supports the diagnosis of acute infection, whereas the par vovirus B19–specific IgG suggests immunity. Addition of parvovirus B19 in vitro to cultures of erythroid progenitor cells completely abolishes erythroid colony formation. Primary infection causes lifelong immunity; however, it is possible that a latent virus may persist in a healthy individual for years.

A transient aplastic crisis is a typical complication of a primary parvovirus B19 infection in patients with increased red cell turnover (usually chronic hemolysis, e.g., hemoglobinopathies, and hereditary red blood cell [RBC] membrane disorders, e.g., hereditary spherocytosis). In typical cases, acute reticulocytopenia results in a sudden drop in hemoglobin (Hb)/hematocrit levels as RBC destruction is not supported by a suppressed marrow. Occasionally, characteristic giant pronormoblasts may be seen in marrow aspirates (Fig. 1). Aplastic crisis is often self-limiting with the evolution of a protective IgG response. Viral titers in the serum of affected patients may be high.

Fig1. PARVOVIRUS B19–MEDIATED PURE RED CELL APLASIA. (A) Bone marrow biopsy and (B) bone marrow aspirate demonstrated giant pronormoblasts.

A more chronic form, parvovirus B19–related PRCA, may develop in immunocompromised patients as, for example, in acquired immunodeficiency syndrome (AIDS). In such cases, IVIg can produce remarkable responses. High doses of IVIg are required (>2 g/kg) because an insufficient dose may not produce the desired effect. DNA dot blot hybridization is the best diagnostic test for the detection of viremia. Parvovirus B19 can also be detected by polymerase chain reaction (PCR), a routinely available test, but this method may provide a high rate of false-positive results. However, if negative, it excludes B19 parvovirus–mediated disease. Improved tests have been developed that allow for the detection of neutralizing antibodies and infectivity of parvovirus B19.

Several other viral infections, including viral hepatitis (A and C), Epstein-Barr virus (EBV), cytomegalovirus (CMV), human T-Lymphotropic virus (HTLV)-1, and human immunodeficiency virus (HIV), have been implicated as causative agents of PRCA. Little is known about the exact mechanisms underlying these disorders, but they likely involve T-cell–mediated suppression as observed during HTLV-1 infection and EBV or antibody-mediated destruction of RBC precursors, as in hepatitis C–induced PRCA. Frequently the presence of multiple comorbidities and medications makes it difficult to isolate the causative agent of PRCA.

Connective Tissue Disease–Associated Pure Red Cell Aplasia

The majority of connective tissue diseases associated with PRCA are autoimmune in nature. Several rheumatologic diseases have been associated with PRCA, including adult-onset Still disease, derma tomyositis,89 mixed connective tissue disease, polymyositis, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus. The pathogenesis of the PRCA in this setting may vary and includes autoantibody-mediated erythroid inhibition, autoantibody directed against erythropoietin, and CTL-mediated killing of erythroid precursors.

Drug-Induced Pure Red Cell Aplasia

Various chemical agents and drugs have been associated with PRCA. The mechanisms responsible for erythroid inhibition may be diverse depending on the offending agent (Table 1) but may include induction of antibodies targeting the drugs or drugs bound to cellular and plasma proteins. Another possible mechanism involves drug-mediated triggering of T-cell responses, or direct toxicity to the erythroid series as seen with diphenylhydantoin.

Table1. Drugs and Chemicals Implicated in Pure Red  Cell Aplasia

Erythropoietin Antibody–Associated Pure Red Cell Aplasia

Recombinant erythropoietin is used in the treatment of anemia of various origins, including anemia of chronic disease, renal disease, and a variety of bone marrow failure syndromes, particularly myelodysplastic syndromes (MDS). Cases of PRCA have developed as a consequence of antibody formation against endogenous erythropoietin or while receiving treatment with recombinant erythropoietin. The latter condition has been referred to as epoetin-induced PRCA or EPO-PRCA with initial cases related to exposure to epoetin alpha (Eprex; 92%) and epoetin beta (NeoRecormon; 8%). There are reports of human erythropoietin (HuEpo) neutralizing antibody PRCA related to the use of biosimilar recombinant HuEpo in Thailand. There are several risk factors associated with the development of EPO-PRCA, including subcutaneous (SC) route of administration, use of epoetin alpha stabilized in a human serum albumin (HSA)–free formulation, use of silicone oil as lubricant in prefilled Eprex syringes, and use in patients with chronic renal disease.

This observation has led to modification in the storage, handling, and administration of Eprex favoring IV administration, especially with Eprex stabilized with HSA-free formulation, and avoidance of the SC non-HSA–stabilized Eprex. Diagnostic criteria have also been proposed incorporating major features (treatment with epoetin for at least 3 weeks, decrease in Hb by 0.1 g/dL/day without transfusions or transfusion requirement of about 1 unit/week to keep Hb levels stable, reticulocyte count less than 10 × 10⁹/L, no major drop in other blood lineages), minor features (skin and systemic allergic reactions), and accessory investigations to exclude other causes. The most commonly used tests to detect antibodies are enzyme-linked immunosorbent assay, radioimmunoprecipitation assay, and surface plasmon resonance. Once antibodies are detected, their neutralizing ability is tested using an in vitro bioassay. Following establishment of diagnosis, management should include discontinuation of exogenous erythropoietin, administration of immunosuppressive agents, or, in cases of anemia secondary to renal insufficiency, renal transplantation.

Pure Red Cell Aplasia Following Allogeneic Stem Cell Transplantation

In contrast to HLA matching, ABO blood group incompatibility plays a minor role in the success of allogeneic hematopoietic stem cell transplantation (HSCT). However, PRCA may be associated with major ABO incompatibility between the donor and recipient, leading to inhibition of donor erythroid precursors by residual host isoagglutinins. This complication is more commonly observed following the use of nonmyeloablative conditioning regimens. PRCA may also be resistant to the withdrawal or decrease of immunosuppression, or donor lymphocyte infusions. Responses to rituximab, erythropoietin, plasma exchange, and azathioprine have been reported. A case responsive to a purified CD34+ cell infusion has also been reported. Multiple cases of successful treatment with daratumumab (IgG1k monoclonal antibody directed against CD38) have also been reported. Resolution of PRCA is generally associated with a decrease and subsequent disappearance of host isoagglutinins.

Pure Red Cell Aplasia Associated With Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a rare X-linked recessive condition typically seen during infancy. Clinical features may include type 1 diabetes mellitus, eczema, and autoimmune hepatitis. Anemia can be severe at diagnosis because the fall in Hb occurs over a protracted period of time and patients often exhibit a good degree of adaptation. Arrest of erythropoiesis is obvious with a profound reticulocytopenia.

اخر الاخبار

اخبار العتبة العباسية المقدسة

قسم الهدايا والنذور يباشر خياطة أوشحة المشاركات في حفل سن التكليف الشرعي

مؤسسة القبس: العتبة العباسية المقدسة تسهم في خدمة المجتمع بمختلف المجالات عبر مشاريعها المتنوعة

قسم الشؤون الفكرية يعرض منجزات مراكزه المتخصصة في حفظ التراث المخطوط ضمن فعاليات مهرجان عين الحياة

في مقابلة خاصة.. مديرة مكتب المتولي الشرعي للشؤون النسوية توضح أهداف حفل التكليف الشرعي وأبعاده التربوية

المزيد

الآخبار الصحية

الشاي والقهوة وتدهور الذاكرة.. دراسة تكشف نتائج جديدة

هل يساعد الزنك على تحسين النوم والطاقة؟

علامات يجب عدم تجاهلها بعد تناول مكملات "فيتامين د"

لتجنب ارتفاع سكر الدم.. ما أفضل وقت لتناول الحلوى؟

المزيد

الآخبار التكنلوجية

الإمارات ترسخ مكانتها كأحد أبرز قادة الذكاء الاصطناعي عالميا !

"أوبن إيه آي" تحذر المشرعين الأميركيين من تحايل "ديب سيك" ؟

تصاعد التوتر بين "أبل" وإدارة ترامب.. ما السبب؟

سلاح طبي في ساحات الحرب.. رذاذ يوقف النزيف خلال ثانية !

المزيد

مواضيع ذات صلة

Pathophysiology of Paroxysmal Nocturnal Hemoglobinuria

Clinical Manifestations of Paroxysmal Nocturnal Hemoglobinuria

Hypothyroidism: Etiology and Treatment

Introduction and History of Paroxysmal Nocturnal Hemoglobinuria

Diseases of The Central Nervous System

Diseases of The Oral Cavity

Diseases of The Upper Respiratory Tract

Hyperthyroidism: Etiology and Treatment

Clinical Features of Hyper- and Hypothyroidism

Clinical Associations of Aplastic Anemia

Typical and Atypical Presentations of Aplastic Anemia

Pathophysiologic Pathways Leading to Aplastic anemia